We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study

    Uttiya Deb

    Pharmacology, Burdwan Medical College, Burdwan, 713104, India

    ,
    Sandip Mukhopadhyay

    *Author for correspondence: Tel.: +91 988 882 1984;

    E-mail Address: sandipcmcl@gmail.com

    Pharmacology, Burdwan Medical College, Burdwan, 713104, India

    ,
    Biswamit Bhattacharya

    Radiation Oncology, Burdwan Medical College, Burdwan, 713104, India

    ,
    Sanatan Banerjee

    Radiation Oncology, Burdwan Medical College, Burdwan, 713104, India

    &
    Supreeti Biswas

    Pharmacology, Burdwan Medical College, Burdwan, 713104, India

    Published Online:https://doi.org/10.2217/fon-2020-0853

    The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL). A prospective randomized controlled study was conducted, enrolling 80 cancer patients experiencing moderate or severe fatigue following at least three cycles of chemotherapy or a course of palliative/curative radiotherapy. Patients received either oral modafinil 100 mg or dexamethasone 4 mg daily for 14 days. Levels of fatigue, QoL and symptom severity were compared after 14–21 days. Both drugs were efficacious and safe in the management of fatigue and QoL. However, modafinil performed marginally better. Although modafinil demonstrated marginal superiority, both modafinil and dexamethasone can improve fatigue and QoL in cancer patients.

    Clinical trials registry of India: CTRI/2018/05/014046 (www.ctri.nic.in)

    Lay abstract

    Cancer-related fatigue is a common and nagging problem that needs best evidence-based management. Modafinil, a brain stimulant, and dexamethasone, a corticosteroid, have been shown in separate studies to provide benefit, but there are little data regarding which one is superior. The present study compared modafinil with dexamethasone in a randomized controlled trial. Modafinil was found to be marginally superior in treating cancer-related fatigue and several domains of quality of life, though dexamethasone also demonstrated significant improvement of fatigue. This study provides a valuable guide for future larger studies for implementation of the findings in the form of better patient care.

    Tweetable abstract

    Oral doses of the #psychostimulant #modafinil and #corticosteroid #dexamethsasone can improve #cancer-related #fatigue and #qualityoflife without major #sideeffects. #Modafinil was marginally superior.

    References

    • 1. Ferlay J, Colombet M, Soerjomataram I et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144(8), 1941–1953 (2019).
    • 2. Weis J. Cancer-related fatigue: prevalence, assessment and treatment strategies. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 441–446 (2011).
    • 3. Banipal RPS, Singh H, Singh B. Assessment of cancer-related fatigue among cancer patients receiving various therapies: a cross-sectional observational study. Indian J. Palliat. Care 23(2), 207–211 (2017).
    • 4. Hickok JT, Roscoe JA, Morrow GR, Mustian K, Okunieff P, Bole CW. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer 104(8), 1772–1778 (2005).
    • 5. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J. Natl Cancer Inst. Monographs (32), 40–50 (2004).
    • 6. Jean-Pierre P, Mustian K, Kohli S, Roscoe JA, Hickok JT, Morrow GR. Community-based clinical oncology research trials for cancer-related fatigue. J. Support Oncol. 4(10), 511–516 (2006).
    • 7. Berger AM, Mooney K, Banerjee Chandana O. NCCN clinical practice guidelines in oncology (NCCN guidelines®) version 2.2020 cancer-related fatigue. J. Natl Compr. Canc. Netw. 65 (2020).
    • 8. Olson K. A new way of thinking about fatigue: a reconceptualization. Oncol. Nurs. Forum 34(1), 93–99 (2007).
    • 9. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl. 1), 4–10 (2007).
    • 10. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4(2), 82–96 (1996).
    • 11. Hofman M, Morrow GR, Roscoe JA et al. Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices. Cancer 101(4), 851–857 (2004).
    • 12. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 18(4), 743–753 (2000).
    • 13. Jones JM, Olson K, Catton P et al. Cancer-related fatigue and associated disability in post-treatment cancer survivors. J. Cancer Surviv. 10(1), 51–61 (2016).
    • 14. Yennurajalingam S, Palmer JL, Zhang T, Poulter V, Bruera E. Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer 16(10), 1125–1130 (2008).
    • 15. Smets EM, Visser MR, Willems-Groot AF et al. Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br. J. Cancer 78(7), 899–906 (1998).
    • 16. Yucel B, Akkaş EA, Okur Y et al. The impact of radiotherapy on quality of life for cancer patients: a longitudinal study. Support Care Cancer 22(9), 2479–2487 (2014).
    • 17. Fosså SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J. Clin. Oncol. 21(7), 1249–1254 (2003).
    • 18. Vardy JL, Dhillon HM, Pond GR et al. Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. Ann. Oncol. 27(9), 1761–1767 (2016).
    • 19. Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12(Suppl. 1), 11–21 (2007).
    • 20. Berger AM, Mooney K. Dissemination and implementation of guidelines for cancer-related fatigue. J. Natl Compr. Canc. Netw. 14(11), 1336–1338 (2016).
    • 21. Mercadante S, Fulfaro F, Casuccio A. The use of corticosteroids in home palliative care. Support Care Cancer 9(5), 386–389 (2001).
    • 22. Tanioka H, Miyamoto Y, Tsuji A et al. Prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer (KSCC1402/HGCSG1402). Oncology 94(5), 289–296 (2018).
    • 23. Yennurajalingam S, Frisbee-Hume S, Palmer JL et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J. Clin. Oncol. 31(25), 3076–3082 (2013).
    • 24. Shih A, Jackson KC. Role of corticosteroids in palliative care. J. Pain Palliat. Care Pharmacother. 21(4), 69–76 (2007).
    • 25. Yennurajalingam S, Bruera E. Role of corticosteroids for fatigue in advanced incurable cancer: is it a “wonder drug” or “deal with the devil”. Curr. Opin. Support Palliat. Care 8(4), 346–351 (2014).
    • 26. Sodji Q, Kaminski J, Willey C et al. Management of metastatic spinal cord compression. South. Med. J. 110(9), 586–593 (2017).
    • 27. Yennurajalingam S, Tannir NM, Williams JL et al. A double-blind, randomized, placebo-controlled trial of panax ginseng for cancer-related fatigue in patients with advanced cancer. J. Natl Compr. Canc. Netw. 15(9), 1111–1120 (2017).
    • 28. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic treatment of cancer-related fatigue. Oncologist 12(Suppl. 1), 43–51 (2007).
    • 29. Boele FW, Douw L, de Groot M et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro. Oncol. 15(10), 1420–1428 (2013).
    • 30. Cooper MR, Bird HM, Steinberg M. Efficacy and safety of modafinil in the treatment of cancer-related fatigue. Ann. Pharmacother. 43(4), 721–725 (2009).
    • 31. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat. Med. 23(4), 325–331 (2009).
    • 32. Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve 39(3), 297–303 (2009).
    • 33. Lam JY, Freeman MK, Cates ME. Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Ann. Pharmacother. 41(6), 1005–1012 (2007).
    • 34. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J. Neurol. 249(8), 983–987 (2002).
    • 35. Spathis A, Fife K, Blackhall F et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J. Clin. Oncol. 32(18), 1882–1888 (2014).
    • 36. Laird BJA, Scott AC, Colvin LA et al. Pain, depression, and fatigue as a symptom cluster in advanced cancer. J. Pain Symptom Manage. 42(1), 1–11 (2011).
    • 37. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin. Hematol. 34(3 Suppl. 2), 13–19 (1997).
    • 38. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11(3), 570–579 (1993).
    • 39. Bruera E, Kuehn N, Miller MJ, Selmser P, MacMillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J. Palliat. Care 7(2), 6–9 (1991).
    • 40. Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. J. Pain Symptom Manage. 53(3), 630–643 (2017).
    • 41. Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CCD. Cut points on 0–10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment scale in cancer patients: a systematic review. J. Pain Symptom Manage. 45(6), 1083–1093 (2013).
    • 42. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Uppsala Monitoring Centre (UMC), WHO Collaborating Centre for International Drug Monitoring. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
    • 43. Morrow GR, Gillies LJ, Hickok JT, Roscoe JA, Padmanaban D, Griggs JJ. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed. J. Clin. Oncol. 23(Suppl. 16), 8012–8012 (2005).
    • 44. Jean-Pierre P, Morrow GR, Roscoe JA et al. A Phase 3 randomized, placebo-controlled, double-blind clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116(14), 3513–3520 (2010).
    • 45. Fukuoka S, Shitara K, Noguchi M et al. Prophylactic use of oral dexamethasone to alleviate fatigue during regorafenib treatment for patients with metastatic colorectal cancer. Clin. Colorectal Cancer 16(2), e39–e44 (2017).
    • 46. Inoue A, Yamada Y, Matsumura Y et al. Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11(8), 528–532 (2003).
    • 47. Kaleita TA, Wellisch DK, Graham CA et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J. Clin. Oncol. 24(Suppl. 18), 1503–1503 (2006).
    • 48. Morrow GR, Gillies LJ, Hickok JT, Roscoe JA, Padmanaban D, Griggs JJ. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed. J. Clin. Oncol. 23(Suppl. 16), 8012–8012 (2005).
    • 49. Locke DEC, Decker PA, Sloan JA et al. Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J. Pain Symptom Manage. 34(6), 628–638 (2007).
    • 50. Vetter TR, Mascha EJ. Bias, confounding, and interaction: lions and tigers and bears, oh my! Anesth. Analg. 125(3), 1042–1048 (2017).
    • 51. Administration. Biases and confounding. (2010). https://www.healthknowledge.org.uk/public-health-textbook/research-methods/1a-epidemiology/biases
    • 52. Prajapati K, Desai M, Shah S, Panchal J, Kapadia J, Dikshit R. An analysis of serious adverse drug reactions at a tertiary care teaching hospital. Perspect. Clin. Res. 7(4), 181–186 (2016).
    • 53. Modi A, Desai M, Shah S, Shah B. Analysis of cutaneous adverse drug reactions reported at the regional ADR monitoring center. Indian J. Dermatol. 64(3), 250 (2019).
    • 54. Khan LM, Al-Harthi SE, Osman A-MM, Sattar MAAA, Ali AS. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm. J. 24(4), 485–493 (2016).
    • 55. Du W, Lehr VT, Lieh-Lai M et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J. Clin. Pharmacol. 53(1), 87–95 (2013).